Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by stock analysts at BTIG Research to a “strong-buy” rating in a report released on Monday,Zacks.com reports.
A number of other research analysts have also weighed in on GLX. Benchmark upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 31st. Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th.
Check Out Our Latest Stock Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Stock Splits, Do They Really Impact Investors?
- Beware of BigBear.ai: Insiders Are Selling—Should You?
- How to Use the MarketBeat Dividend Calculator
- CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
- What is a support level?
- Congress! Who Traded What During the Tariff-Induced Meltdown
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
